The promise and challenges of genomics-informed periodontal disease diagnoses.
diagnosis
genomic
periodontitis
Journal
Periodontology 2000
ISSN: 1600-0757
Titre abrégé: Periodontol 2000
Pays: Denmark
ID NLM: 9313276
Informations de publication
Date de publication:
28 Jul 2024
28 Jul 2024
Historique:
revised:
16
05
2024
received:
18
02
2024
accepted:
07
06
2024
medline:
29
7
2024
pubmed:
29
7
2024
entrez:
29
7
2024
Statut:
aheadofprint
Résumé
Recent advances in human genomics and the advent of molecular medicine have catapulted our ability to characterize human and health and disease. Scientists and healthcare practitioners can now leverage information on genetic variation and gene expression at the tissue or even individual cell level, and an enormous potential exists to refine diagnostic categories, assess risk in unaffected individuals, and optimize disease management among those affected. This review investigates the progress made in the domains of molecular medicine and genomics as they relate to periodontology. The review summarizes the current evidence of association between genomics and periodontal diseases, including the current state of knowledge that approximately a third of the population variance of periodontitis may be attributable to genetic variation and the management of several monogenic forms of the disease can be augmented by knowledge of the underlying genetic cause. Finally, the paper discusses the potential utility of polygenic risk scores and genetic testing for periodontitis diagnosis now and in the future, in light of applications that currently exist in other areas of medicine and healthcare.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860‐921.
Nurk S, Koren S, Rhie A, et al. The complete sequence of a human genome. Science. 2022;376:44‐53.
Liao W‐W, Asri M, Ebler J, et al. A draft human pangenome reference. Nature. 2023;617:312‐324.
Guigó R. Genome annotation: from human genetics to biodiversity genomics. Cell Genomics. 2023;3:100375.
McCarthy JJ, McLeod HL, Ginsburg GS. Genomic medicine: a decade of successes, challenges, and opportunities. Sci Transl Med. 2013;5. doi:10.1126/scitranslmed.3005785
Gorlov IP, Gorlova OY, Amos CI. Allelic spectra of risk SNPs are different for environment/lifestyle dependent versus independent diseases. PLoS Genet. 2015;11:e1005371.
Heinzen EL, Ge D, Cronin KD, et al. Tissue‐specific genetic control of splicing: implications for the study of complex traits. PLoS Biol. 2008;6:e1.
Liu Z, Zhu L, Roberts R, Tong W. Toward clinical implementation of next‐generation sequencing‐based genetic testing in rare diseases: where are we? Trends Genet. 2019;35:852‐867.
Wright CF, McRae JF, Clayton S, et al. Making new genetic diagnoses with old data: iterative reanalysis and reporting from genome‐wide data in 1,133 families with developmental disorders. Genet Med. 2018;20:1216‐1223.
Iversen ES, Lipton G, Clyde MA, Monteiro ANA. Functional annotation signatures of disease susceptibility loci improve SNP association analysis. BMC Genomics. 2014;15:398.
Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl Res. 2009;154:277‐287.
MacRae CA, Vasan RS. The future of genetics and genomics: closing the phenotype gap in precision medicine. Circulation. 2016;133:2634‐2639.
Divaris K. Fundamentals of precision medicine. Compend Contin Educ Dent. 2017;38:30‐32.
Divaris K. The era of the genome and dental medicine. J Dent Res. 2019;98:949‐955.
Institute of Medicine (US). Genome‐Based Therapeutics. National Academies Press; 2012. doi:10.17226/13436
Aronson SJ, Rehm HL. Building the foundation for genomics in precision medicine. Nature. 2015;526:336‐342.
Wang RC, Wang Z. Precision medicine: disease subtyping and tailored treatment. Cancers (Basel). 2023;15:3837.
Schwalfenberg GK. A review of the critical role of vitamin D in the functioning of the immune system and the clinical implications of vitamin D deficiency. Mol Nutr Food Res. 2011;55:96‐108.
Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747‐752.
Satam H, Joshi K, Mangrolia U, et al. Next‐generation sequencing technology: current trends and advancements. Biology (Basel). 2023;12:997.
Suwinski P, Ong C, Ling MHT, Poh YM, Khan AM, Ong HS. Advancing personalized medicine through the application of whole exome sequencing and big data analytics. Front Genet. 2019;10:10. doi:10.3389/fgene.2019.00049
Xi X, Li T, Huang Y, et al. RNA biomarkers: frontier of precision medicine for cancer. Noncoding RNA. 2017;3:3. doi:10.3390/ncrna3010009
Tsimberidou AM, Fountzilas E, Bleris L, Kurzrock R. Transcriptomics and solid tumors: the next frontier in precision cancer medicine. Semin Cancer Biol. 2022;84:50‐59.
Munoz J, Swanton C, Kurzrock R. Molecular Profiling and the Reclassification of Cancer: Divide and Conquer. American Society of Clinical Oncology Educational Book; 2013:127‐134.
Takahashi T, Sakai K, Kenmotsu H, et al. Predictive value of EGFR mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy. Cancer Sci. 2022;113:287‐296.
Zhang X, Zhang Y, Tang H, He J. EGFR gene copy number as a predictive/biomarker for patients with non‐small‐cell lung cancer receiving tyrosine kinase inhibitor treatment: a systematic review and meta‐analysis. J Investig Med. 2017;65:72‐81.
Bonomi PD, Gandara D, Hirsch FR, et al. Predictive biomarkers for response to EGFR‐directed monoclonal antibodies for advanced squamous cell lung cancer. Ann Oncol. 2018;29:1701‐1709.
Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014;2014:1‐9.
Pernas S, Tolaney SM. HER2‐positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol. 2019;11:175883591983351.
Dillman RO. Perceptions of Herceptin®: a monoclonal antibody for the treatment of breast cancer. Cancer Biother Radiopharm. 1999;14:5‐10.
Hamdan D, Nguyen TT, Leboeuf C, Meles S, Janin A, Bousquet G. Genomics applied to the treatment of breast cancer. Oncotarget. 2019;10:4786‐4801.
Filippini DM, Pagani R, Tober N, et al. HER2‐targeted therapies for salivary gland cancers. Oral Oncol. 2024;148:106612.
Sud A, Turnbull C, Houlston R. Will polygenic risk scores for cancer ever be clinically useful? NPJ Precis Oncol. 2021;5:40.
Fu R, Harris EL, Helfand M, Nelson HD. Estimating risk of breast cancer in carriers of BRCA 1 and BRCA 2 mutations: a meta‐analytic approach. Stat Med. 2007;26:1775‐1787.
Jain S, Gradishar WJ. The application of Oncotype DX in early‐stage lymph‐node‐positive disease. Curr Oncol Rep. 2014;16:360.
Lyman GH, Cosler LE, Kuderer NM, Hornberger J. Impact of a 21‐gene RT‐PCR assay on treatment decisions in early‐stage breast cancer. Cancer. 2007;109:1011‐1018.
Cescon DW, Bratman SV, Chan SM, Siu LL. Circulating tumor DNA and liquid biopsy in oncology. Nat Can. 2020;1:276‐290.
Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575:299‐309.
Tsui L‐C, Dorfman R. The cystic fibrosis gene: a molecular genetic perspective. Cold Spring Harb Perspect Med. 2013;3:a009472.
Veit G, Avramescu RG, Chiang AN, et al. From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol Biol Cell. 2016;27:424‐433.
Castellani C, Cuppens H, Macek M, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros. 2008;7:179‐196.
Brodlie M, Haq IJ, Roberts K, Elborn JS. Targeted therapies to improve CFTR function in cystic fibrosis. Genome Med. 2015;7:101.
Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor–Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373:220‐231.
Brewington JJ, McPhail GL, Clancy JP. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction. Expert Rev Respir Med. 2016;10:5‐17.
McLaren PJ, Fellay J. HIV‐1 and human genetic variation. Nat Rev Genet. 2021;22:645‐657.
Naranbhai V, Carrington M. Host genetic variation and HIV disease: from mapping to mechanism. Immunogenetics. 2017;69:489‐498.
Shafer RW. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev. 2002;15:247‐277.
Ni J, Wang D, Wang S. The CCR5‐Delta32 genetic polymorphism and HIV‐1 infection susceptibility: a meta‐analysis. Open Medicine. 2018;13:467‐474.
Ryder SP. #CRISPRbabies: notes on a scandal. CRISPR J. 2018;1:355‐357.
Baylis F, Darnovsky M, Hasson K, Krahn TM. Human germline and heritable genome editing: the global policy landscape. CRISPR J. 2020;3:365‐377.
Divaris K. Searching deep and wide: advances in the molecular understanding of dental caries and periodontal disease. Adv Dent Res. 2019;30:40‐44.
Schaefer AS. Genetics of periodontitis: discovery, biology, and clinical impact. Periodontology 2000. 2018;78:162‐173.
Bostanci N, Belibasakis GN. Precision periodontal care: from omics discoveries to chairside diagnostics. Clin Oral Investig. 2023;27:971‐978.
Divaris K, Moss K, Beck JD. Biologically informed stratification of periodontal disease holds the key to achieving precision oral health. J Periodontol. 2020;91(Suppl 1):S50‐S55.
Papapanou PN, Sanz M, Buduneli N, et al. Periodontitis: consensus report of workgroup 2 of the 2017 world workshop on the classification of periodontal and Peri‐implant diseases and conditions. J Periodontol. 2018;89. doi:10.1002/JPER.17-0721
Tonetti MS, Sanz M. Implementation of the new classification of periodontal diseases: decision‐making algorithms for clinical practice and education. J Clin Periodontol. 2019;46:398‐405.
Bostanci N, Belibasakis GN. Gingival crevicular fluid and its immune mediators in the proteomic era. Periodontology 2000. 2018;76:68‐84.
Taba M, Kinney J, Kim AS, Giannobile WV. Diagnostic biomarkers for Oral and periodontal diseases. Dent Clin N Am. 2005;49:551‐571.
Sorsa T, Gursoy UK, Nwhator S, et al. Analysis of matrix metalloproteinases, especially MMP‐8, in gingival crevicular fluid, mouthrinse and saliva for monitoring periodontal diseases. Periodontology 2000. 2016;70:142‐163.
Rudick CP, Lang MS, Miyamoto T. Understanding the pathophysiology behind chairside diagnostics and genetic testing for IL‐1 and IL‐6. Oral Dis. 2019;25:1879‐1885.
Agler CS, Divaris K. Sources of bias in genomics research of oral and dental traits. Community Dent Health. 2020;37:102‐106.
Baer PN. The case for Periodontosis as a clinical entity. J Periodontol. 1971;42:516‐520.
Melnick M, Shields ED, Bixler D. Periodontosis: a phenotypic and genetic analysis. Oral Surg Oral Med Oral Pathol. 1976;42:32‐41.
Marazita ML, Burmeister JA, Gunsolley JC, Koertge TE, Lake K, Schenkein HA. Evidence for autosomal dominant inheritance and race‐specific heterogeneity in early‐onset periodontitis. J Periodontol. 1994;65:623‐630.
Kinane DF, Hart TC. Genes and gene polymorphisms associated with periodontal disease. Crit Rev Oral Biol Med. 2003;14:430‐449.
Hewitt C, McCormick D, Linden G, et al. The role of cathepsin C in Papillon‐Lefèvre syndrome, prepubertal periodontitis, and aggressive periodontitis. Hum Mutat. 2004;23:222‐228.
Nibali L, Almofareh SA, Bayliss‐Chapman J, Zhou Y, Vieira AR, Divaris K. Heritability of periodontitis: a systematic review of evidence from animal studies. Arch Oral Biol. 2020;109:104592.
Nashef A, Qabaja R, Salaymeh Y, et al. Integration of murine and human studies for mapping periodontitis susceptibility. J Dent Res. 2018;97:537‐546.
Shungin D, Haworth S, Divaris K, et al. Genome‐wide analysis of dental caries and periodontitis combining clinical and self‐reported data. Nat Commun. 2019;10:2773.
Munz M, Chen H, Jockel‐Schneider Y, et al. A haplotype block downstream of plasminogen is associated with chronic and aggressive periodontitis. J Clin Periodontol. 2017;44(10):962‐970.
Silva LM, Doyle AD, Greenwell‐Wild T, et al. Fibrin is a critical regulator of neutrophil effector function at the oral mucosal barrier. Science. 2021;374:eabl5450.
Morelli T, Agler CS, Divaris K. Genomics of periodontal disease and tooth morbidity. Periodontology 2000. 2020;82:143‐156.
Nibali L, Di Iorio A, Tu Y‐K, Vieira AR. Host genetics role in the pathogenesis of periodontal disease and caries. J Clin Periodontol. 2017;44(Suppl 18):S52‐S78.
McCarthy MI, Abecasis GR, Cardon LR, et al. Genome‐wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet. 2008;9:356‐369.
Divaris K, Haworth S, Shaffer JR, et al. Phenotype harmonization in the GLIDE2 Oral health genomics consortium. J Dent Res. 2022;101:1408‐1416.
Shaddox LM, Morford LA, Nibali L. Periodontal health and disease: the contribution of genetics. Periodontology 2000. 2021;85:161‐181.
Agler CS, Shungin D, Ferreira Zandoná AG, et al. Protocols, methods, and tools for genome‐wide association studies (GWAS) of dental traits. Methods Mol Biol. 2019;1922:493‐509.
Haghgoo R, Mehran M, Banakar M. Recent developments in the diagnosis, treatment, and management of Papillon‐Lefèvre syndrome. Evid Based Dent. 2023. doi:10.1038/s41432-023-00932-1
Erzurumluoglu AM, Alsaadi MM, Rodriguez S, et al. Proxy molecular diagnosis from whole‐exome sequencing reveals Papillon‐Lefevre syndrome caused by a missense mutation in CTSC. PLoS One. 2015;10:e0121351.
Roessler HI, Knoers NVAM, van Haelst MM, van Haaften G. Drug repurposing for rare diseases. Trends Pharmacol Sci. 2021;42:255‐267.
Bullón P, Castejón‐Vega B, Román‐Malo L, et al. Autophagic dysfunction in patients with Papillon‐Lefèvre syndrome is restored by recombinant cathepsin C treatment. J Allergy Clin Immunol. 2018;142:1131‐1143.e7.
Fischer A. Gene therapy for inborn errors of immunity: past, present and future. Nat Rev Immunol. 2023;23:397‐408.
Silva LM, Divaris K, Bugge TH, Moutsopoulos NM. Plasmin‐mediated fibrinolysis in periodontitis pathogenesis. J Dent Res. 2023;102:972‐978.
Nibali L, Pelekos G, D'Aiuto F, et al. Influence of IL‐6 haplotypes on clinical and inflammatory response in aggressive periodontitis. Clin Oral Investig. 2013;17:1235‐1242.
Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin‐6 (IL‐6) gene on IL‐6 transcription and plasma IL‐6 levels, and an association with systemic‐onset juvenile chronic arthritis. J Clin Invest. 1998;102:1369‐1376.
Van Dyke TE, Bartold PM, Reynolds EC. The nexus between periodontal inflammation and Dysbiosis. Front Immunol. 2020;11:511.
Offenbacher S, Jiao Y, Kim SJ, et al. GWAS for interleukin‐1β levels in gingival crevicular fluid identifies IL37 variants in periodontal inflammation. Nat Commun. 2018;9:3686.
Yu J, Hu S. On the ultimate finishing line of the human genome project. Innovation (Cambridge (Mass)). 2021;2:100133.
Kiffel J, Anolik R, Kowalski A. A Clinician's guide to 23andMe: a survey‐based study on People's attitudes and actions towards direct‐to‐consumer genetic testing. Stratford Campus Research Day. 2023;74. https://rdw.rowan.edu/stratford_research_day/2023/may4/74
Kornman KS, Crane A, Wang HY, et al. The interleukin‐1 genotype as a severity factor in adult periodontal disease. J Clin Periodontol. 1997;24:72‐77.
Higashi MK, Veenstra DL, del Aguila M, Hujoel P. The cost‐effectiveness of interleukin‐1 genetic testing for periodontal disease. J Periodontol. 2002;73:1474‐1484.
Huynh‐Ba G, Lang NP, Tonetti MS, Salvi GE. The association of the composite IL‐1 genotype with periodontitis progression and/or treatment outcomes: a systematic review. J Clin Periodontol. 2007;34:305‐317.
Ioannidis JPA. Preventing tooth loss with biannual dental visits and genetic testing: does it work? J Am Dent Assoc. 2015;146:141‐143.
McGrath S, Ghersi D. Building towards precision medicine: empowering medical professionals for the next revolution. BMC Med Genet. 2016;9:23.
Ginsburg GS, Phillips KA. Precision medicine: from science to value. Health Aff (Millwood). 2018;37:694‐701.
Schenkein HA. Finding genetic risk factors for periodontal diseases: is the climb worth the view? Periodontology 2000. 2002;30:79‐90.
Stark Z, Schofield D, Martyn M, et al. Does genomic sequencing early in the diagnostic trajectory make a difference? A follow‐up study of clinical outcomes and cost‐effectiveness. Genet Med. 2019;21:173‐180.
Zhang L, Bao Y, Riaz M, et al. Population genomic screening of all young adults in a health‐care system: a cost‐effectiveness analysis. Genet Med. 2019;21:1958‐1968.
Valencic E, Smid A, Jakopin Z, Tommasini A, Mlinaric‐Rascan I. Repositioning drugs for rare immune diseases: hopes and challenges for a precision medicine. Curr Med Chem. 2018;25:2764‐2782.
Wang Y, Tsuo K, Kanai M, Neale BM, Martin AR. Challenges and opportunities for developing more generalizable polygenic risk scores. Annu Rev Biomed Data Sci. 2022;5:293‐320.
Loika Y, Irincheeva I, Culminskaya I, Nazarian A, Kulminski AM. Polygenic risk scores: pleiotropy and the effect of environment. Geroscience. 2020;42:1635‐1647.
de Coo A, Cruz R, Quintela I, et al. Genome‐wide association study of stage III/IV grade C periodontitis (former aggressive periodontitis) in a Spanish population. J Clin Periodontol. 2021;48:896‐906.
Van der Velden U, Abbas F, Van Steenbergen TJ, et al. Prevalence of periodontal breakdown in adolescents and presence of Actinobacillus actinomycetemcomitans in subjects with attachment loss. J Periodontol. 1989;60(11):604‐610.
Van der Velden U, Abbas F, Armand S, et al. Java project on periodontal diseases. The natural development of periodontitis: risk factors, risk predictors and risk determinants. J Clin Periodontol. 2006;33(8):540‐548.
Petit MD, van Steenbergen TJ, Timmerman MF, de Graaff J, van der Velden U. Prevalence of periodontitis and suspected periodontal pathogens in families of adult periodontitis patients. J Clin Periodontol. 1994;21(2):76‐85.